A retrospective cohort study to investigate the incidence of cachexia in colorectal cancer patients
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000035002
- Lead Sponsor
- ONO PHARMACEUTICAL CO., LTD.
- Brief Summary
Cumulative incidence of cancer cachexia was 50.7% at 24 weeks, and reached 91.3% over the whole study period. OS was significantly different between patients with and without cancer cachexia within 24 weeks after starting first-line treatment, although the onset of cancer cachexia within 24 weeks could not be considered as an independent prognostic factor for OS. Severe appetite loss and fatigue tended to occur more frequently in patients with cancer cachexia within 24 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Not provided
Patients who meet at least one of the following exclusion criteria are not included. 1) Patients who underwent surgical operation of the gastrointestinal tract within the last 6 months, excluding colostomy and stent placement in the gastrointestinal tract 2) Patients with weight loss distinctly caused by a gastrointestinal transit disorder 3) Patients with simultaneously active, double cancer (Stage I intraepithelial carcinoma, intramucosal carcinoma, superficial bladder carcinoma, or other cancers without recurrence for 5 years or more can be registered) 4) Patients with missing of weight data over 12 weeks at the time of visit and during the subsequent medical consultation period 5) Patients who underwent puncture for ascitic fluid at the beginning of initial systemic chemotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method